COMPANY PROFILE

Synovo

Explore full profile

A pharmaceutical discovery services company

Tübingen, GermanyFounded 2004Biotech & Life Sciences

Valuation $50–100M Last recorded · 2024

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Synovo

Synovo GmbH is a drug discovery company based in Germany, focusing on inflammation and innate immune processes. The company operates in the pharmaceutical and biotechnology sectors, serving researchers and professionals seeking to enhance their pre-clinical data sets. Synovo's business model revolves around providing specialized services in synthetic chemistry, pharmacology, analytics, immunology, neurology, and biochemistry. By collaborating with a global network of research partners, Synovo contributes to health improvement through the development of novel therapeutic options for unmet medical needs. Revenue is generated by offering advanced research services and assays, including those for SARS-CoV-2 RNA and antibodies. The company emphasizes interdisciplinary teamwork and community engagement, promoting an active lifestyle among its employees.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2004
Headquarters: Tübingen, Germany
Employees: 29
Open positions: None listed
Dealroom signal: 71.8/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Medical Technology, Research, Biotechnology, Research and Development, Spinout, Biotech and Pharma, Horizon Europe, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Oct 2024	$14M	$57M	Lauxera Capital Partners	—
GRANT✓Other financing	Oct 2018	$603K	—	Horizon 2020 FET (Future and Emerging Technologies)	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Synovo website traffic

Latest recorded traffic for Synovo is 1.1K monthly website visits, up 77.4% over the last three months. Synovo's team declined 3.3% over the past year.

Latest monthly visits1.1K 3-month web change+77.4% 1-year team growth-3.3%

Monthly website visitsNov 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
QPQubit PharmaceuticalsQuantum physics and AI-driven drug discovery platform	Paris, France	Operational	57	$26M	$70M
STSeekyo TherapeuticsA privately-owned biotech company developing a Smart Chemotherapy, selective to tumours, safe for patients	Saint-Maur-des-Fossés, France	Operational
TUTubulisGenerates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology	Planegg, Germany	Acquired
PHPharmaceleraQuantum mechanics and AI powered drug discovery platform	Barcelona, Spain	Operational
MTMuvon TherapeuticsMuvon Therapeutics is creating an autologous cell therapy for damaged skeletal muscles in SUI patients, with a primary focus on developing a safe treatment for stress urinary incontinence in women	Zurich, Switzerland	Operational
IPINEYE PHARMASustained-release ocular insert for chronic eye diseases.	Coimbra, Portugal	Operational
APAbarceo PharmaDeveloping small molecule technology platform for the treatment of mitochondrial dysfunction, with an initial focus on T2D	Malmö kommun, Sweden	Operational
ABArthex BiotechFocused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs	Paterna, Spain	Operational